Standout Papers

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a rand... 2012 2026 2016 2021 865
  1. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
    Alasdair Coles, Cary Twyman et al. The Lancet

Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 22

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
Why do patients with cancer die?
2024 Standout
2 intermediate papers

Works of Pedro Oyuela being referenced

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
2012 Standout
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
2011

Author Peers

Author Last Decade Papers Cites
Pedro Oyuela 923 358 286 360 16 1.2k
Cary Twyman 811 294 238 322 17 994
M. Stojanovic 806 268 250 358 18 1.0k
Tamara Miller 788 283 247 318 23 939
Amy Pace 966 289 281 535 15 1.2k
William H. Stuart 968 520 208 335 18 1.3k
Bella Ertik 747 268 237 287 7 913
Paul O’Connor 912 282 293 326 22 1.1k
C. H. Polman 782 249 264 371 12 896
Peter Alping 751 311 116 337 13 913
A. Guseo 678 272 178 315 24 980

All Works

Loading papers...

Rankless by CCL
2026